• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

    10/15/24 6:00:16 PM ET
    $CAMP
    Get the next $CAMP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Polaris Management Co. VII, L.L.C.

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE, 8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Camp4 Therapeutics Corp [ CAMP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/15/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/15/2024 C(1) 1,250,061 A (1) 1,250,061 I See footnote(2)
    Common Stock 10/15/2024 C(1) 87,448 A (1) 87,448 I See footnote(3)
    Common Stock 10/15/2024 C(4) 353,718 A (4) 1,603,779 I See footnote(2)
    Common Stock 10/15/2024 C(4) 24,745 A (4) 112,193 I See footnote(3)
    Common Stock 10/15/2024 P 909,090 A $11 909,090 I See footnote(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Prime Preferred Stock (1) 10/15/2024 C 14,020,475 (1) (1) Common Stock 1,250,061 (1) 0 I See Footnote(2)
    Series A Prime Preferred Stock (1) 10/15/2024 C 980,829 (1) (1) Common Stock 87,448 (1) 0 I See Footnote(3)
    Series B Preferred Stock (4) 10/15/2024 C 3,967,234 (4) (4) Common Stock 353,718 (4) 0 I See Footnote(2)
    Series B Preferred Stock (4) 10/15/2024 C 277,536 (4) (4) Common Stock 24,745 (4) 0 I See Footnote(3)
    1. Name and Address of Reporting Person*
    Polaris Management Co. VII, L.L.C.

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE, 8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Polaris Partners VII, L.P.

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE, 8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Polaris Entrepreneurs' Fund VII, L.P.

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE
    8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Polaris Partners X, L.P.

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE, 8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Polaris Partners GP X, L.L.C.

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE, 8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    SCHULMAN AMY W

    (Last) (First) (Middle)
    ONE MARINA PARK DRIVE, 8TH FLOOR

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
    2. The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
    3. The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
    4. On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
    5. The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
    Remarks:
    PP X's purchase of the Issuer's common stock was also reported on a Form 3 filed by PPGP X, PP X, and the PPGP X Managing Members on the date hereof. Brian Chee is a managing member of PPGP X and in his capacity as such would be considered a reporting person. Mr. Chee is not listed as a reporting person herein because he does not have codes for the EDGAR system at this time.
    /s/ Lauren Crockett, as attorney-in-fact for Polaris Management Co. VII, L.L.C., general partner of Polaris Partners VII, L.P. 10/15/2024
    /s/ Lauren Crockett, as attorney-in-fact for Polaris Management Co. VII, L.L.C. 10/15/2024
    /s/ Lauren Crockett, as attorney-in-fact for Polaris Management Co. VII, L.L.C., general partner of Polaris Entrepreneurs' Fund VII, L.P. 10/15/2024
    /s/ Lauren Crockett, as general counsel of Polaris Partners GP X, L.L.C., general partner of Polaris Partners X, L.P. 10/15/2024
    /s/ Lauren Crockett, as general counsel of Polaris Partners GP X, L.L.C. 10/15/2024
    /s/ Lauren Crockett, as attorney-in-fact for Brian Chee 10/15/2024
    /s/ Lauren Crockett, as attorney-in-fact for Amy Schulman 10/15/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CAMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    12/22/2021$14.00 → $10.00Buy → Hold
    Craig-Hallum
    9/24/2021$16.00 → $14.00Buy
    Craig Hallum
    6/25/2021$19.00 → $18.50Buy
    Roth Capital
    More analyst ratings

    $CAMP
    Leadership Updates

    Live Leadership Updates

    See more
    • CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

      With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

      3/18/25 8:00:00 AM ET
      $CAMP
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalAmp Appoints Chris Adams as President and Chief Executive Officer

      IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

      1/8/24 6:30:00 AM ET
      $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

      4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/22/24 5:31:39 PM ET
      $CAMP
    • Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 6:34:47 PM ET
      $CAMP
    • Large owner Ah Equity Partners Bio I, L.L.C. converted options into 1,398,067 shares and bought $7,999,992 worth of shares (727,272 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 5:05:20 PM ET
      $CAMP

    $CAMP
    SEC Filings

    See more
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/16/25 6:28:22 AM ET
      $CAMP
    • SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

      SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      5/14/25 1:45:31 PM ET
      $CAMP
    • SEC Form 10-Q filed by CAMP4 Therapeutics Corporation

      10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:26:54 PM ET
      $CAMP

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Bumcrot David

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:09:40 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Medical Officer Maricich Yuri

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:08:11 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Financial Officer Gold Kelly

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:07:07 PM ET
      $CAMP

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th

      5/16/25 6:00:00 AM ET
      $CAMP
    • CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

      Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0

      5/13/25 4:05:11 PM ET
      $CAMP
    • CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three

      4/28/25 4:30:00 PM ET
      $CAMP

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 6:49:57 PM ET
      $CAMP
    • SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

      SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 5:50:56 PM ET
      $CAMP
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 4:19:08 PM ET
      $CAMP
    • William Blair initiated coverage on CAMP4 Therapeutics

      William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

      11/5/24 7:23:37 AM ET
      $CAMP
    • Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

      Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

      11/5/24 6:14:46 AM ET
      $CAMP
    • JP Morgan initiated coverage on CAMP4 Therapeutics with a new price target

      JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

      11/5/24 6:14:20 AM ET
      $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    See more
    • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

      IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

      1/9/24 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

      IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

      12/26/23 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

      IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

      12/18/23 4:31:00 PM ET
      $CAMP